Imagenetix plans to evaluate Celadrin capsules for patients with knee osteoarthritis

By Elaine Rigoli

Tampa, Fla., March 20 - Imagenetix, Inc. announced Monday that it has commissioned a new multi-site study to measure the effectiveness of its Celadrin oral capsules for improving overall joint health in patients with osteoarthritis of the knee.

The primary purpose of this study is to confirm the positive clinical results, published in 2002 in the Journal of Rheumatology, demonstrating that Celadrin oral capsules improved range of motion and overall function in knee osteoarthritis patients.

The upcoming 60-day, double-blind, placebo-controlled trial is expected to be completed this summer, according to a company news release.

The trial, involving 84 patients currently diagnosed with moderate to severe knee osteoarthritis, will be studied in Northridge, Calif., and Ellicott City, Md., operated by Medicus Research, a private clinical trials facility.

Celadrin supports the lubrication of joints and enhances fluids that cushion bones and joints, the release said.

Clinical research published recently in both Journal of Rheumatology and Journal of Strength & Conditioning Research demonstrated that knee osteoarthritis patients using topical administration of Celadrin cream had significant improvement in knee range of motion, balance, mobility and overall knee function, without side effects, according to the release.

San Diego-based Imagenetix develops, formulates and produces nutritional supplements, over-the-counter topical creams, skin care products and pharmaceuticals for inflammatory-related markets.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.